20
Participants
Start Date
September 24, 2021
Primary Completion Date
September 30, 2026
Study Completion Date
September 30, 2027
Polatuzumab Vedotin
Polatuzumab vedotin will be administered as an IV infusion at 1.8mg/kg on Day 1 of each cycle, every 21 days.
Rituximab
Rituximab will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Etoposide
Etoposide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Prednisone
Prednisone will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. Prednisone will be given orally.
Cyclophosphamide
Cyclophosphamide will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
Hydroxydaunomycin
Hydroxydaunomycin will be obtained from commercial supply, and will be given for a total of 6 cycles for all patients. The drug will be given by IV route.
RECRUITING
Mount Sinai- Icahn School of Medicine, New York
RECRUITING
Columbia University Medical Center, New York
RECRUITING
Weill Cornell Medicine, New York
RECRUITING
Ohio state University, Columbus
Collaborators (1)
Genentech, Inc.
INDUSTRY
Weill Medical College of Cornell University
OTHER